Bard Views GI, AAA Devices And Brachytherapy Seeds As Key Growth Drivers
This article was originally published in The Gray Sheet
Executive Summary
Bard is hopeful that the Health Care Financing Administration will deem the firm's endoscopic suturing system for gastroesophageal reflux disease eligible for supplementary reimbursement under the agency's outpatient prospective payment system.